The stark reality of global healthcare economics emerges as new Alzheimer's treatments face pricing decisions worldwide. While these breakthrough therapies offer hope for millions of families, their economic value differs dramatically based on where patients live, creating profound equity challenges in access to potentially life-changing care.
Analysis of lecanemab and donanemab across 174 countries reveals that value-based pricing should range from as little as $4 annually in low-income nations to nearly $14,000 in high-income countries. The drugs demonstrated modest but meaningful benefits, extending quality-adjusted life years by 0.38 and 0.51 respectively compared to standard care. However, the 2,000-fold pricing differential reflects vast disparities in healthcare spending capacity and cost-effectiveness thresholds between nations.
This economic modeling represents a critical step toward rational drug pricing in an era of expensive neurological therapies. Traditional pharmaceutical pricing often ignores local economic realities, potentially pricing out entire populations from accessing treatments. The value-based framework provides a data-driven foundation for pricing negotiations, though implementation faces significant challenges. Pharmaceutical companies must balance research and development costs against global market access, while healthcare systems grapple with budget constraints and competing priorities. The analysis also highlights limitations inherent in quality-adjusted life year calculations, which may not fully capture the broader societal benefits of slowing cognitive decline. As these first-generation Alzheimer's treatments enter markets worldwide, this pricing framework could establish precedent for future neurological therapies, influencing both innovation incentives and global health equity.